App-Quantinova.ai

Expression levels of orexin receptor 1 in different stages of colorectal cancer

Ana M. Wielandt - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Neuropeptides

Functional studies of the prostaglandin E2 receptor EP4 in ovarian cancer

Joceyln C. Reader - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Dinoprostone

Interleukin-17 acts through MMP7 to promote prostate cancer

Qiuyang Zhang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Interleukin

Forerunner genes contribute to bladder carcinogenesis by altering the basal to luminal urothelial transition program

Sangkyou Lee - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Role of Gli2 in mediating the progression of prostate cancer to CRPC

Lu Xia - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Solid malignancies

Doxycycline

Mutational and copy number profiling of cancer-related genes in 26 human tumor xenografts and their correlations with antitumor drug sensitivities

Takashi Kobunai - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Capecitabine

Orthotopic syngeneic tumor models for preclinical evaluation of cancer immunotherapy strategies

Juan Zhang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

RNAseq and FACS profiling of syngeneic mouse models treated with immune checkpoint inhibitors enable biomarker discovery and model selection for cancer immunotherapy

Lan Zhang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Determinants of response to temozolomide in an exceptionally sensitive patient derived model

Lara H. el Touny - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Temozolomide

Development of a humanized mouse model for direct evaluation of anti-human PD-L1 antibodies

Meng Qiao - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics using the tumor marker Rgs16::GFP

Ozhan Ocal - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Efficacy study of APX3330, a Ref-1 redox inhibitor, and Gemcitabine in a mouse pancreatic ductal adenocarcinoma model

Kyle C. McElyea - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Solid malignancies

Gemcitabine

MiXeno Humanized Mouse Model as an Efficient Tool to Evaluate in Vivo Activity of Anti-Cancer Immunotherapeutics

Juan Zhang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Development of patient-derived xenograft (PDX) models for pancreatic carcinoma as a preclinical platform for drug development

Jill Ricono - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Gemcitabine

PET imaging of trastuzumab emtansine (T-DM1) drug delivery to intracranial patient derived xenograft (PDX) models of breast cancer metastasis

Carsten Haagen Nielsen - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Trastuzumab emtansine

Identification of molecular predictors of differential chemotherapy response using patient-derived xenografts

Michael T. Lewis - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A Mouse-Human co-clinical trial with patient-derived xenograft (PDX) models demonstrates a predictive signature for dovitinib (TKI258), an FGFR and VEGFR inhibitor,in lung squamous cell carcinomalung cancer (LSCC)

Hye Ryun Kim - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Dovitinib

Novel patient-derived xenograft and primary tissue culture cells for preclinical study in sarcoma

Xiaoqing Pan - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma

Jessica L. Teh - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Palbociclib

Preclinical model of patient-derived tumor xenograft in humanized mice

Annika Wulf-Goldenberg - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts